Dendritic cell-based vaccines for pancreatic cancer and melanoma

Annals of the New York Academy of Sciences

Volumn 1174, Issue , 2009, Pages 33-40

  Mulé, James J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Chemokines; Dendritic cells; Immunotherapy; Melanoma; Pancreatic cancer; TNF ; Vaccines

Indexed keywords

DENDRITIC CELL VACCINE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; CANCER VACCINE; CHEMOKINE; GAMMA CHEMOKINE; SECONDARY LYMPHOID TISSUE CHEMOKINE; XCL1 PROTEIN, HUMAN;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DENDRITIC CELL; DRUG DELIVERY SYSTEM; EXTERNAL BEAM RADIOTHERAPY; GENE THERAPY; HUMAN; MELANOMA; PANCREAS CANCER; TUMOR IMMUNITY; ANIMAL; ARTICLE; BONE MARROW TRANSPLANTATION; IMMUNOLOGY; IMMUNOTHERAPY; LYMPH NODE; METHODOLOGY; MOUSE; PANCREAS TUMOR; SKIN; SKIN TUMOR; WHOLE BODY RADIATION;

ANIMALIA;

ANIMALS; BONE MARROW TRANSPLANTATION; CANCER VACCINES; CHEMOKINE CCL21; CHEMOKINES; CHEMOKINES, C; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; LYMPH NODES; MELANOMA; MICE; PANCREATIC NEOPLASMS; SKIN; SKIN NEOPLASMS; WHOLE-BODY IRRADIATION;

EID: 70350474687     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04936.x     Document Type: Conference Paper

References (30)

1. Fields, R.C., K. Shimizu & J.J. Mulé. 1998. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. USA 95: 9482-9487.
2. Shimizu, K., R. Fields, M. Giedlin, et al. 1999. Systemic administration of interleukin-2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl. Acad. Sci. USA 96: 2268-2273. (Pubitemid 29117903)
3. Asavaroengchai, W., Y. Kotera & J.J. Mulé. 2002. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc. Natl. Acad. Sci. USA 99: 931-936. (Pubitemid 34106613)
4. Mulé, J.J. 2000. Dendritic cells: At the clinical crossroads (Invited Commentary). J. Clin. Invest. 105: 707-708.
5. Weber, J.S. & J.J. Mulé. 2001. How much help does a vaccine-induced T cell response need? (Invited Commentary). J. Clin. Invest. 107: 553-554.
6. Maine, G.N. & J.J. Mulé. 2002. Making room for T cells. (Invited Commentary). J. Clin. Invest. 110: 161-164.
7. Mulé, J.J. & J.S. Weber. 2004. Translation of cancer immunotherapies. Nat. Med. 10: 1153.
8. Sondak, V.K., M.S. Sabel & J.J Mulé. 2006. Melanoma vaccines: Where have we been and where are we going? Clin. Cancer Res. 12: 2337-2341.
9. Anasetti, C. & J.J. Mulé. 2007. To ablate or not to ablate? HSCs in the T cell driver's seat. (Invited Commentary). J. Clin. Invest. 117: 306-310.
10. Coppola, D. & J.J. Mulé. 2008. Ectopic "lymph nodes" within human solid tumors (Invited Editorial). J. Clin. Oncol. 26: 4369-4370.
11. Mulé, J.J., M.C. Custer, B. Averbook, et al. 1996. Genetic modification of a murine fibrosarcoma to secrete the chemotactic cytokine RANTES: Loss of tumorigenicity in vivo is dependent upon host immune cells. Hum. Gene Ther. 7: 1545-1553.
12. Kirk, C.J., D. Hartigan-O'Connor, B.J. Nickoloff, et al. 2001. T cell dependent immunity mediated by secondary lymphoid tissue chemokine (SLC): Augmentation of dendritic cell based immunotherapy. Cancer Res. 61: 2062-2070.
13. Kirk, C.J, D. Hartigan-O'Connor & J.J. Mulé. 2001. The dynamics of the T cell antitumor response: chemokine secreting dendritic cells can prime tumor reactive T cells extranodally. Cancer Res. 61: 8794-8802.
14. Terando, A., B. Roessler & J.J. Mulé. 2004. Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector. Cancer Gene Ther. 11: 165-173. (Pubitemid 38280519)
15. American Cancer Society. 2004. Cancer Facts and Figures. American Cancer Society, Atlanta.
16. Sener, S.F., A. Fremgen, H.R. Menck, et al. 1999. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J. Am. Coll. Surg. 189: 1-7.
17. Burris, H.A., M.J Moore, J Andersen, et al. 1997. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15: 2403-2413.
18. Laheru, D. & EM. Jaffee. 2005. Immunotherapy for pancreatic cancer - science driving clinical progress. Nat. Rev. Cancer 5: 459-467. (Pubitemid 40791488)
19. Chang, A.E., B.G. Redman, J.R. Whitfield, et al. 2002. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 8: 1021-1032.
20. Geiger, J.D., R.J Hutchinson, L. Hohenkirk, et al. 2001. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 61:8513-8519.
21. Geiger, J., R. Hutchinson, L. Hohenkirk, et al. 2000. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 356: 1163-1165. (Pubitemid 30769387)
22. Candido, K.A., K. Shimizu, J.C. McLaughlin, et al. 2001. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res. 61: 228-236.
23. Shimizu, K., M. Giedlin & J.J. Mulé. 2001. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helperprotein. Cancer Res. 61: 2618-2624. (Pubitemid 32685847)
24. Timmerman, J.M. & R. Levy. 2000. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J. Immunol. 164: 4797-4803.
25. Corti, A. &M. Ponzoni. 2004. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann. N. Y. Acad. Sci 1028: 104-112.
26. Mocellin, S., C.R. Rossi, P. Pilati, et al. 2005. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 16: 35-53. (Pubitemid 40279116)
27. Mundt, A.J., S. Vijayakumar, J. Nemunaitis, et al. 2004. A phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin. Cancer Res. 10: 5747-5753. (Pubitemid 39180951)
28. Hallahan, D.E., H.J. Mauceri, L.P. Seung, et al. 1995. Spatial and temporal control of gene therapy using ionizing radiation. Nat. Med. 1: 786-791.
29. Hanna, N., JR. Hecht, S. Vogel, et al. 2004. Safety and efficacy of TNFerade in unresectable, locally advanced pancreatic cancer (LAPC): Results of the first two cohorts of a dose escalating study. J. Clin. Oncol. 22, No14S, 3038.
30. Chi, K.H., S.J. Liu, C.P. Li, et al. 2005. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J. Immunother. 28: 129-135.